Ascletis gains preclinical HCV candidate

Medivir AB (SSE:MVIR B) granted Ascletis BioScience Co. Ltd. (Hangzhou, China) exclusive development and commercialization rights in Greater China to preclinical HCV candidate MIV-802. Medivir received an upfront payment and is eligible for milestones and tiered royalties.

MIV-802 is a pan-genotypic uridine nucleotide HCV NS5B polymerase inhibitor. Trek Therapeutics PBC (Cambridge, Mass.) has rights to the compound outside of Taiwan and China from Medivir...